Pfizer Appoints New Directors, CAO Departs

Ticker: PFE · Form: 8-K · Filed: 2024-07-01T00:00:00.000Z

Sentiment: neutral

Topics: executive-change, board-election, governance

Related Tickers: PFE

TL;DR

Pfizer's CAO is out, a new interim CAO is in, and two new directors are joining the board.

AI Summary

On June 27, 2024, Pfizer Inc. filed an 8-K report detailing the departure of its Chief Accounting Officer, Michael G. McLellan, effective June 28, 2024. The company also announced the appointment of Sally Susman as Interim Chief Accounting Officer. Additionally, the filing disclosed the election of two new directors, Dr. Roslyn M. Brock and Dr. Robert M. Califf, to its Board of Directors, effective July 1, 2024.

Why It Matters

Changes in key executive positions and board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: low — The filing primarily concerns routine executive and board changes, with no immediate financial distress or significant operational disruptions indicated.

Key Players & Entities

FAQ

Who has been appointed as the interim Chief Accounting Officer at Pfizer?

Sally Susman has been appointed as the interim Chief Accounting Officer.

When was Michael G. McLellan's departure as Chief Accounting Officer effective?

Michael G. McLellan's departure was effective June 28, 2024.

Who are the two new directors elected to Pfizer's Board?

Dr. Roslyn M. Brock and Dr. Robert M. Califf have been elected as new directors.

What is the effective date for the election of the new directors?

The election of the new directors is effective July 1, 2024.

What is the primary purpose of this Form 8-K filing?

This Form 8-K filing reports the departure of a director/officer, election of directors, and compensatory arrangements of certain officers.

From the Filing

0000078003-24-000127.txt : 20240701 0000078003-24-000127.hdr.sgml : 20240701 20240701080718 ACCESSION NUMBER: 0000078003-24-000127 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240627 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240701 DATE AS OF CHANGE: 20240701 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PFIZER INC CENTRAL INDEX KEY: 0000078003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 135315170 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-03619 FILM NUMBER: 241088233 BUSINESS ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 BUSINESS PHONE: 2127332323 MAIL ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 FORMER COMPANY: FORMER CONFORMED NAME: PFIZER CHARLES & CO INC DATE OF NAME CHANGE: 19710908 8-K 1 pfe-20240627.htm 8-K JUNE 27, 2024 pfe-20240627 0000078003 false 0000078003 2024-06-27 2024-06-27 0000078003 us-gaap:CommonStockMember 2024-06-27 2024-06-27 0000078003 pfe:NotesDue20271.000Member 2024-06-27 2024-06-27 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.  20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 27, 2024 PFIZER INC . (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number) Identification No.) incorporation)     66 Hudson Boulevard East 10001-2192 New York, New York (Zip Code) (Address of principal executive offices) Registrant’s telephone number, including area code: ( 212 ) 733-2323 (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $.05 par value PFE New York Stock Exchange 1.000% Notes due 2027 PFE27 New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company     ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Election of Mr. Taraporevala to the Board of Directors On June 27, 2024, the Board of Directors (the “Board”) of Pfizer Inc. (the “Company”) elected Cyrus Taraporevala to serve as a member of the Company’s Board, effective immediately. In addition, he was appointed to

View on Read The Filing